Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: Implications for risk-stratification

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 222-228

  Costa, Luciano J ^a   Nista, Elizabeth J ^b   Buadi, Francis K ^c   Lacy, Martha Q ^c   Dispenzieri, Angela ^c   Kramer, Cindy P ^b   Edwards, Kathy H ^b   Kang, Yubin ^a   Gertz, Morie A ^c   Stuart, Robert K ^a   Kumar, Shaji ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

CD34; Filgrastim; Multiple myeloma; Plerixafor; Stem cell mobilization

Indexed keywords

CD34 ANTIGEN; LENALIDOMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER PATIENT; CLINICAL FEATURE; COHORT ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; PREDICTIVE VALUE; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; VALIDATION STUDY;

CD34; FILGRASTIM; MULTIPLE MYELOMA; PLERIXAFOR; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES;

EID: 84893110083     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.003     Document Type: Article

References (31)

1. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med 2003, 348:1875-1883.
2. Attal M., Harousseau J.L., Stoppa A.M., et al. Aprospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. NEngl J Med 1996, 335:91-97.
3. Palumbo A., Bringhen S., Petrucci M.T., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104:3052-3057.
4. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. JClin Oncol 2005, 23:9227-9233.
5. Raje N., Powles R., Horton C., et al. Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer 1997, 75:1684-1689.
6. Greenbaum A.M., Link D.C. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 2011, 25:211-217.
7. Christopher M.J., Liu F., Hilton M.J., et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood 2009, 114:1331-1339.
8. Costa L.J., Miller A.N., Alexander E.T., et al. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011, 46:523-528.
9. Gertz M.A., Kumar S.K., Lacy M.Q., et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009, 43:619-625.
10. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
11. Costa L.J., Kramer C., Hogan K.R., et al. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012, 52:2375-2381.
12. Costa L.J., Alexander E.T., Hogan K.R., et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011, 46:64-69.
13. Micallef I.N., Sinha S., Gastineau D.A., et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013, 19:87-93.
14. Sinha S., Gastineau D., Micallef I., et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011, 46:943-949.
15. Villa C.H., Shore T., Van Besien K., Cushing M. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield. Biol Blood Marrow Transplant 2012, 18:1867-1875.
16. Nademanee A.P., DiPersio J.F., Maziarz R.T., et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 2012, 18:1564-1572.
17. Costa L.J., Abbas J., Hogan K.R., et al. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant 2012, 47:1403-1408.
18. Dingli D., Nowakowski G.S., Dispenzieri A., et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006, 6:384-388.
19. Mark T., Stern J., Furst J.R., et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008, 14:795-798.
20. Demirer T., Buckner C.D., Gooley T., et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996, 17:937-941.
21. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
22. Popat U., Saliba R., Thandi R., et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009, 15:718-723.
23. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008, 22:1282-1284.
24. Wuchter P., Ran D., Bruckner T., et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16:490-499.
25. Goldschmidt H., Hegenbart U., Wallmeier M., et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997, 98:736-744.
26. Boccadoro M., Palumbo A., Bringhen S., et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002, 87:846-850.
27. Shapiro J, Perkins J, Bookout R, etal. Evaluation of a risk-based algorithm for the utilization of plerixafor as primary mobilization of CD34+ cells in autologous hematopoietic cell transplant candidates. [ASH Annual Meeting Abstracts] Blood 2011;118:4060.
28. Li J., Hamilton E., Vaughn L., et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011, 51:2175-2182.
29. Abhyankar S., Dejarnette S., Aljitawi O., et al. Arisk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2011, 47:483-487.
30. Vishnu P., Roy V., Paulsen A., Zubair A.C. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2011, 52:55-62.
31. Giralt S., Costa L., Schriber J., et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2013, (Epub ahead of print). 10.1016/j.bbmt.2013.10.013.